Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy (Kid-MaCareOnco)

University Hospital Basel

Status: Completed

Conditions: Kidney Impairment

Treatments: Other: blood test for renal biomarkers; Other: urine test for renal biomarkers

Study type: Observational

Funder types: Other

Identifiers

NCT04308642

2019-02143 ks19Pfister;

Details and patient eligibility

About

This study is to investigate blood and urine kidney injury markers (especially Uromodulin) in pediatric cancer patients treated with nephrotoxic chemotherapy. Uromodulin is a marker to detect and monitor tubular injury and renal function.

Enrollment: 6 patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• signed informed consent by their-selves (≥ 14 years) or their legal representatives (< 14 years or in case of lacking capacity of judgement)
• cancer diagnosis, that indicates a nephrotoxic chemotherapy including the drugs High Dose MTX (HD-MTX), ifosfamide, cis- and carboplatin.

Exclusion criteria

• critically-ill patients with inotropic and/or vasopressor drugs
• signs of severe Sepsis
• receiving other nephrotoxic drugs parallel to the chemotherapy cycle